Clinical Trial Update: Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo [Phase 3]

View source ↗

Summary

Phase 3 study assessing safety and immunogenicity of Ebola vaccine candidates Ad26.ZEBOV and MVA-BN-Filo completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ad26.ZEBOV
• MVA-BN-Filo

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Ebola Virus Disease | Phase 3 | Status: COMPLETED | Results posted: 2022-07-18